NS 3623: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9954236 |
| CHEMBL ID | 4303572 |
| SCHEMBL ID | 1462393 |
| MeSH ID | M0384363 |
| Synonym |
|---|
| 1-[4-bromo-2-(2h-tetrazol-5-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]urea |
| SCHEMBL1462393 |
| ns 3623 |
| ns3623 |
| ns-3623 |
| gtpl7660 |
| n-[4-bromo-2-(1h-tetrazol-5-yl-phenyl]-n'-[3-(trifluoromethyl)phenyl]-urea |
| 343630-41-1 |
| AKOS024458170 |
| n-(4-bromo-2-(1h-tetrazol-5-yl)-phenyl)-n'-(3'-trifluoromethylphenyl) urea |
| EX-A5263 |
| NCGC00379133-01 |
| jxpuldiatmtiin-uhfffaoysa-n |
| Q27088060 |
| 1-(4-bromo-2-(2h-tetrazol-5-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea , |
| HY-108586 |
| CS-0029252 |
| CHEMBL4303572 |
| 1-(3-trifluoromethylphenyl)-3-(2-(1h-tetrazol-5-yl)-4-bromophenyl)urea |
| urea, n-(4-bromo-2-(2h-tetrazol-5-yl)phenyl)-n'-(3-(trifluoromethyl)phenyl)- |
| n-(4-bromo-2-(1h-tetrazol-5-yl-phenyl)-n'-(3-(trifluoromethyl)phenyl)-urea |
| unii-j9hb2t5ss4 |
| j9hb2t5ss4 , |
| urea, n-(4-bromo-2-(1h-tetrazol-5-yl)phenyl)-n'-(3-(trifluoromethyl)phenyl)- |
| BS-52711 |
| 1-(4-bromo-2-(1h-tetrazol-5-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea |
| 1-[4-bromo-2-(1h-1,2,3,4-tetrazol-5-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]urea |
| EN300-25086386 |
| F76482 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Repeated administration of 100 mg/kg twice a day for 10 days caused no adverse effects; therefore, this regimen was chosen as the highest dosing for the SAD mice." | ( Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Asakura, T; Bennekou, P; Brugnara, C; Christophersen, P; de Franceschi, L; Evans, G; Lian, L; Pedersen, O, 2001) | 0.31 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 8.4866 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 37.9083 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| Interferon beta | Homo sapiens (human) | Potency | 37.9083 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346751 | Human Kv11.1 (Voltage-gated potassium channels) | 2006 | Molecular pharmacology, Oct, Volume: 70, Issue:4 | Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea]. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.83) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||